INTRODUCTION 1
Silver-Russell syndrome (SRS, MIM 180860) is a genetically and clinically heterogeneous 2 condition characterized by intrauterine and postnatal growth retardation, dysmorphic facial 3 features and body asymmetry [1] . 35-60% of SRS cases show hypomethylation of the H19 4 imprinting control region (H19-ICR; Fig. 1a ) at11p15, which is believed to result in reduced 5 expression of IGF2 (MIM 147470) [2] [3] [4] . The underlying causes of hypomethylation include 6 mosaic maternal uniparental disomy (UPD) of chromosome 11 [5] , maternal duplication of 7 11p15 [6, 7] , and possibly gene mutations of , but is unknown in most cases. In 8 most SRS patients hypomethylation occurs at both H19-ICR and IGF2P0, but is occasionally 9 restricted to H19-ICR or IGF2P0 [9] . 10
The H19-ICR is located within the H19 promoter and is normally methylated on the 11 paternally-derived allele. H19 (MIM 103280) encodes a maternally-expressed non-coding 12 RNA while IGF2 encodes the paternally-expressed growth factor IGF-II. In mice the 13 endodermal enhancers of IGF2 are located +10 kb from H19 transcription start site; skeletal 14 muscle and mesodermal enhancers are located at +35 kb and other mesodermal enhancers at 15 +120 kb [10] . The interaction of these enhancer sequences with the promoters of H19 or 16 IGF2 is modulated by CTCF for which the H19-ICR contains seven potential binding sites 17 [11] . CTCF binding to unmethylated H19-ICR prevents interaction between the IGF2 18 promoter and enhancers, while methylation of the H19-ICR prevents CTCF binding, enabling 19 the enhancers to interact with the IGF2 promoter. Naturally occurring structural anomalies in 20 the enhancer region of H19/IGF2 in patients are very informative in testing the hypothesis of 21 complex imprinting and competing enhancer regulation of H19 and IGF2 and ultimately help 22 to more clearly define the roles of these genes in humans. We report here for the first time 23 SRS patients with chromosomal structural mutations in the H19/IGF2 enhancer region. 24
25

METHODS 1
Patients 2 Patient 1 was referred for SRS testing at the age of 2 years due to pre-and postnatal growth 3 retardation, characteristic dysmorphic features, congenital anomalies and failure to thrive. 4
Patient 2 was referred at age 14 weeks with pre-and postnatal growth retardation, typical 5 facial features and severe feeding difficulties. Subsequently his sister (patient 3) presented 6 neonatally with the same clinical features. Patient 4 was identified after karyotyping due to 7 recurrent miscarriages. She had pre-and postnatal growth retardation and atypical diabetes, 8 but there was no clinical suspicion of SRS. Informed consent for the investigations performed 9 and publication was obtained for all patients. Patients 1 and 4 were recruited via the initial 10 diagnostic testing, while patients 2 and 3 were recruited into the research study "Imprinting 11 and performed essentially as previously described [13] . Briefly, primary amplification 7 reactions (50μl, performed in duplicate) contained forward and reverse primers, one of which 8 was biotinylated, Titanium Taq and buffer (Clontech, Mountain View, Ca. USA), and ~20ng 9 bisulphite-treated DNA. After 45 amplification cycles, 20μl single-stranded biotinylated PCR 10 products were pyrosequenced using Pyrosequencing Gold Reagents (Biotage) according to 11 the manufacturer's instructions. The percentage methylation at each CpG site was determined 12 by AQ software. AQ levels >5% were indistinguishable from background fluorescence. In 13 each pyrosequencing assay, a bisulphite treatment control was included in the form of a 14 cytosine not in a CpG dinucleotide; this would be expected to be converted entirely to uracil. Array CGH analysis (aCGH) used a custom 8 X 60K Agilent array (Agilent Technologies, 1 South Queensferry, UK) designed to densely cover known human imprinted loci. Probes 2 were designed using Agilent Technologies' e-Array design tool with the following filters 3 applied: Tm filter, similarity filter and catalog probe preference. Across the region 4 chr11:1,674,000-2,979,000 (hg18) probes were tightly tiled to provide maximum resolution 5
with an average spacing of 50nt. The remainder of chr11 was represented by Agilent aCGH 6 control probes, which provide a genome-wide backbone to enable efficient normalization. 7 aCGH was performed according to the manufacturer's instructions. Briefly, 500ng of blood 8 genomic DNA was labeled using the genomic DNA enzymatic labeling kit, hybridized to the 9 array for 24 hours and subsequently washed. Arrays were scanned using an Agilent 10
Technologies' DNA microarray scanner G2539A and data extracted using Agilent 11
Technologies' Feature Extraction software version 10.5. 
RESULTS
23
The clinical features of the patients are summarized in Table 1 . Cytogenetic analysis of 24 patient 1 showed a normal karyotype, 46,XY while MLPA analysis showed deletion of H19 25 8 and part of H19-ICR (Fig. 1a) ; the peak height of the deleted probes suggested mosaicism, 1 while MLPA analysis of parental DNA was normal, suggesting that the deletion had arisen de 2 novo. Microsatellite analysis showed reduced dosage ratios of D11S4046 (paternal:maternal 3 ratio 1:2.3) consistent with mosaicism (Fig. 1c) . Cytogenetic analysis of patients 2 and 3 4 revealed a pericentric inversion of chromosome 11 (karyotypes 46,XY,inv(11)(p15.5q21)pat 5 and 46,XX,inv(11)(p15.5q21)pat, respectively), inherited in both children from their 6 phenotypically normal father. FISH analysis showed a split signal using BAC clone RP11-7 534I22, while fosmids W12-1875E5 and W12-1660M14 hybridized to 11p and 11q, 8 respectively ( Fig. 1a and Fig. 1d ) mapping the 11p15.5 breakpoint to chr11:1,862,216-9 1,921,555 (hg18). 10
Patient 4 had a balanced translocation (karyotype 46,XX,t(1;11)(p36.22;p15.5)). FISH 11 analysis mapped the 11p15.5 breakpoint between W12-1875E5 and W12-1660M14 [14] . 12
Paternal origin of the translocation was inferred through karyotyping of the patient's mother, 13 who had a normal karyotype, and the patient's daughter, who had the same translocation as 14 the patient but normal growth. 15 DNA methylation analysis showed partial hypomethylation of both H19-ICR and IGF2P0 in 16 patient 1. In patients 2, 3 and 4 IGF2P0 was partially hypomethylated while the methylation 17 of H19-ICR was in the normal range (Fig. 1b) . 18
All four patients were analyzed by array CGH (aCGH). In patient 1 aCGH showed a 58.8 kb 19 deletion (chr11:1,918,222-1,977,026 (hg18)) encompassing the endodermal, skeletal muscle 20 specific and part of the mesodermal enhancers, as well as H19 and part of H19-ICR including 21 the seventh CTCF binding site, but not the two repeat blocks (Fig. 1a) , though the log 22 intensity difference suggested a mosaic deletion. In patients 2 and 3 aCGH showed an 8. We present three pedigrees with disruption of the shared H19/IGF2 enhancer region and 6 separation of the mesodermal enhancers from IGF2, one by deletion, one by an inversion 7 breakpoint accompanied by deletion, and one by breakpoint of an apparently balanced 8 translocation. IGF2 expression was reduced in mesodermal tissue in patient 4 [14] . 9
Previously, the small stature of patient 4 was unaccounted for, but we now hypothesize that 10 hypomethylation of IGF2-P0 due to the separation of IGF2 from its enhancers causes growth 11 retardation. The deletion in patient 1 may truncate these enhancers and moreover reduces 12 their distance from IGF2 by 50%, thus potentially affecting the local three-dimensional 13 structure of the DNA and hence its function. We therefore suppose that the mesodermal 14 enhancers are non-functional in all four patients. It is interesting that all four patients are 15 growth-retarded, but only patients 1, 2 and 3, who harbor deletions including the sequence 16 chr11:1,918,312-1,927,132 (hg18), presented with the clinical diagnosis of SRS. One 17 interpretation of this observation is that reduced IGF2 expression from mesodermal 18 enhancers is responsible for only the growth retardation seen in SRS, while other genetic or 19 epigenetic defects cause the other phenotypic traits of SRS. Alternatively, given that SRS is a 20 disorder with marked clinical heterogeneity it may be that patient 4 showed an atypical 21 presentation. 22
It was striking that all patients showed hypomethylation of IGF2P0, while hypomethylation 23 of the H19-ICR was observed only in patient. This observation suggests that IGF2P0 24 methylation may not directly depend on H19-ICR methylation in cis, but may instead reflect 25 the promoter activity of IGF2P0 per se, and be established as a consequence of its interaction 1 with distant IGF2 enhancers. Disruption of the enhancer region represents a possible 2 explanation of rare SRS cases with hypomethylation restricted to IGF2P0 [9] . 3
The effects of deletions and mutations in the H19 region depend not only on their parent of 4 origin, but also on their localization. Deletions or mutations of H19-ICR described to date are 5 apparently without phenotypic effect when on the paternal allele, whereas in maternal 6 inheritance they are associated with the overgrowth disorder Beckwith-Wiedemann syndrome 7 (MIM 130650) [15, 16] . Thus, we hypothesize that a paternal deletion of H19, such as seen in 8 patient 1, may be of less clinical significance than the separation of IGF2 from its enhancers. 9
For the enhancer region, no data have hitherto been presented in humans; however, mice with 10 paternally inherited deletions were 80% of normal size whereas mice with maternal deletions 11 were of normal size [17] . We predict that detailed characterization of the IGF2 promoter and 12 enhancer elements in humans will uncover further genetic and epigenetic changes that 13 predispose to growth retardation and/or SRS. Moreover, we confirm that IGF2P0 14 hypomethylation is found in a proportion of SRS cases with normal H19-ICR methylation. 
